Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $29.4 million.

  • Angiodynamics' Other Operating Expenses changed N/A to $29.4 million in Q4 2025 from the same period last year, while for Nov 2025 it was $60.1 million, marking a year-over-year increase of 80336.49%. This contributed to the annual value of $54.5 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q4 2025, Angiodynamics' Other Operating Expenses is $29.4 million.
  • In the past 5 years, Angiodynamics' Other Operating Expenses registered a high of $47.8 million during Q3 2023, and its lowest value of $6.7 million during Q1 2024.
  • Moreover, its 5-year median value for Other Operating Expenses was $29.2 million (2021), whereas its average is $28.3 million.
  • Data for Angiodynamics' Other Operating Expenses shows a peak YoY increase of 3391.21% (in 2021) and a maximum YoY decrease of 8322.15% (in 2021) over the last 5 years.
  • Angiodynamics' Other Operating Expenses (Quarter) stood at $29.1 million in 2021, then rose by 9.58% to $31.9 million in 2022, then soared by 50.01% to $47.8 million in 2023, then tumbled by 86.09% to $6.7 million in 2024, then skyrocketed by 340.95% to $29.4 million in 2025.
  • Its Other Operating Expenses stands at $29.4 million for Q4 2025, versus $30.8 million for Q3 2025 and $6.7 million for Q1 2024.